In three recent filings, Kevin Kotler’s Broadfin Capital has revealed adding three companies: Corium International Inc (NASDAQ:CORI), AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) and La Jolla Pharmaceutical Company (NASDAQ:LJPC) to its equity portfolio.
A new filing with the Securities and Exchange Commission showed that Broadfin Capital currently owns 1.35 million shares of Corium International Inc (NASDAQ:CORI), representing 7.66% of common stock outstanding.
Corium International Inc (NASDAQ:CORI) is a commercial stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal pharmaceutical products. Earlier in March, the company filed a registration statement on Form S-1 with for a proposed initial public offering of its common stock and later it priced its IPO of 6.50 million shares of common stock at a price to the public of $8.00 per share. The underwriters have been granted a 30-day option to purchase up to 975,000 additional shares of common stock at the IPO price.
In AMAG Pharmaceuticals Inc. (NASDAQ:AMAG), Broadfin Capital owns 1.43 million shares, the stake amasses 6.55% of the common stock. AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) is a specialty pharmaceutical company that markets Feraheme (ferumoxytol) Injection and MuGard Mucoadhesive Oral Wound Rinse in the United States.
Last month, Jacob Gottlieb’s Visium Asset Management disclosed initiating a 1.6 million position in AMAG Pharmaceuticals Inc. (NASDAQ:AMAG). Adage Capital Management, managed by Phill Gross and Robert Atchinson, held 3.80 million shares of the company at the end of 2013.
In another filing, Broadfin Capital disclosed owning a 5.37% passive stake in La Jolla Pharmaceutical Company (NASDAQ:LJPC). The new position contains around 389,900 common stock shares. La Jolla Pharmaceutical Company (NASDAQ:LJPC) is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer.
Earlier this month, the fund revealed a reduced stake in MELA Sciences, Inc (NASDAQ:MELA), owning a total of 9.1 million shares, equal to almost 10% of the common stock, down from over 16% held earlier.
Disclosure: none
Recommended Reading:
Broadfin Capital Initiates Stake in Pernix Therapeutics (PTX)
Kevin Kotler’s Broadfin Capital Initiates Stake in Eleven Biotherapeutics (EBIO) Following Its IPO
Broadfin Capital Initiates a Stake in Retrophin Inc (RTRX) Following Its Listing on NASDAQ